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SARM1, a protein with critical NADase activity, is a central executioner in a conserved 55 
programme of axon degeneration. We report seven rare missense or in-frame microdeletion 56 
human SARM1 variant alleles in patients with amyotrophic lateral sclerosis (ALS) or other 57 
motor nerve disorders that alter the SARM1 auto-inhibitory ARM domain and constitutively 58 
hyperactivate SARM1 NADase activity. The constitutive NADase activity of these seven 59 
variants is similar to that of SARM1 lacking the entire ARM domain and greatly exceeds the 60 
activity of wild-type SARM1, even in the presence of nicotinamide mononucleotide (NMN), 61 
its physiological activator. This rise in constitutive activity alone is enough to promote 62 
neuronal degeneration in response to otherwise non-harmful, mild stress. Importantly, these 63 
strong gain-of-function alleles are completely patient-specific in the cohorts studied and 64 
show a highly significant association with disease at the single gene level. These findings of 65 
disease-associated coding variants that alter SARM1 function build on previously reported 66 
genome-wide significant association with ALS for a neighbouring, more common SARM1 67 
intragenic single nucleotide polymorphism (SNP) to support a contributory role of SARM1 in 68 
these disorders. A broad phenotypic heterogeneity and variable age-of-onset of disease 69 
among patients with these alleles also raises intriguing questions about the pathogenic 70 
mechanism of hyperactive SARM1 variants.  71 




The toll-like receptor adaptor protein SARM1 is required for axon degeneration after injury, 75 
in response to toxins and other insults, and in several models of neurodegenerative disease 76 
(Conforti et al., 2014; Coleman & Höke, 2020). In many of these situations the intimate 77 
interplay between pro-degenerative SARM1 (sterile alpha and TIR motif containing protein 78 
1) (Osterloh et al., 2012; Gerdts et al., 2013) and its upstream, pro-survival regulator 79 
NMNAT2 (nicotinamide mononucleotide adenylyltransferase 2) (Gilley & Coleman, 2010; 80 
Gilley et al., 2015) is critical and most likely involves a disruption to normal nicotinamide 81 
adenine dinucleotide (NAD+) homeostasis (Gerdts et al., 2016; Figley & DiAntonio, 2020) or 82 
related metabolites (Angeletti et al., 2021). NMNAT2 is one of three NMNAT isoforms that 83 
catalyse the last step in NAD+ biosynthesis and is the predominant NMNAT in axons. The 84 
SARM1 TIR domain has a critical NAD+ consuming multifunctional glycohydrolase (NADase) 85 
activity (Essuman et al., 2017; Horsefield et al., 2019; Wan et al., 2019) and, intriguingly, 86 
NMNAT substrate, NMN, and its product, NAD+, can both influence this activity: NMN 87 
activates SARM1 NADase by binding to an allosteric site in the auto-inhibitory ARM domain 88 
of the enzyme (Zhao et al., 2019; Figley et al., 2021), whereas NAD+ can oppose this 89 
activation by competing for binding to the same site (Jiang et al., 2020; Sporny et al., 2020; 90 
Figley et al., 2021). Rising NMN and declining NAD+ as a consequence of loss of very short-91 
lived NMNAT2 in damaged axons (Di Stefano et al., 2015) thus leads directly to activation of 92 
SARM1 NADase and a self-reinforcing NAD+ decline that represents one possible cause of 93 
degeneration. 94 
As well as its established role in axons, SARM1 can promote neuronal cell death 95 
under certain conditions. In most cases, the extent to which cell death and concurrent axon 96 
degeneration are primary or secondary events has not been fully elucidated (Gerdts et al., 97 
2013; Summers et al., 2014; Gerdts et al., 2015; Summers et al., 2016; Bratkowski et al., 98 
2020). However, recent studies do suggest direct involvement of SARM1 in neuronal cell 99 
death in some situations, including photoreceptor loss in models of retinal degeneration and 100 
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Leber congenital amaurosis (LCA) (Ozaki et al., 2020; Sasaki et al., 2020) and as a result of 101 
Vacor neurotoxicity when specifically applied to cell bodies (Loreto et al., 2020).  102 
Extensive evidence from animal models has implicated NMNAT-sensitive and SARM1-103 
dependent axon degeneration and/or cell death in a variety of neurodegenerative disorders 104 
(Conforti et al., 2014; Coleman & Höke, 2020), but knowledge of genetic association with 105 
human diseases is more limited. To date, biallelic NMNAT2 loss-of-function (LoF) variants 106 
have been associated with two rare polyneuropathies that broadly resemble the 107 
corresponding mouse models (Gilley et al., 2013, 2019; Huppke et al., 2019; Lukacs et al., 108 
2019), and NMNAT1 mutations cause photoreceptor loss in LCA via a mechanism involving 109 
SARM1 (Sasaki et al., 2020). While no firm association between SARM1 variation and 110 
human disease has yet been established, genome wide association studies (GWAS) have 111 
linked the SARM1 chromosomal locus, including an intragenic SNP, to sporadic ALS (Fogh 112 
et al., 2014; van Rheenen et al., 2016), although whether SARM1 is the causative gene is 113 
not known. 114 
Motor nerve disorders are neurodegenerative disorders that affect motor neurons in 115 
the brain, brainstem, and spinal cord. These include ALS, the most common adult-onset 116 
motor nerve disorder, as well as other inherited conditions like hereditary spastic paraplegia 117 
(HSP) (Goutman, 2017). There is also some phenotypic and genetic overlap with the 118 
hereditary motor neuropathies (Rossor et al., 2012). These disorders exhibit broad 119 
phenotypic heterogeneity and variable age-of-onset. Recently, SARM1-dependent death 120 
mechanisms have been found to play a significant role in a mutant TDP-43 model of ALS 121 
(White et al., 2019). This is important as TDP-43 aggregation is an almost universal 122 
pathologic feature in ALS (Arai et al., 2006; Neumann et al., 2006). While removal of SARM1 123 
does not alleviate motor neuron degeneration in a SOD1 model of ALS (Peters et al., 2018), 124 
this could be explained by the finding that TDP-43 aggregation is usually not seen in ALS 125 
linked to SOD1 or FUS mutations (Mackenzie et al., 2007; Maekawa et al., 2009; McAlary et 126 
al., 2019). It therefore remains possible that SARM1 plays an important role in a majority of 127 
ALS cases. 128 
 6 
 Here, we have identified a number of rare alleles specific to ALS patients in Project 129 
MinE initiative data freeze 1 (Project MinE ALS Sequencing Consortium, 2018; van der Spek 130 
et al., 2019) and the Answer ALS project (Rothstein, 2020) encoding missense substitutions 131 
and in-frame microdeletions in the auto-inhibitory ARM domain of SARM1 that confer 132 
substantial pro-degenerative NADase gain-of-function (GoF). A number of these GoF alleles 133 
were subsequently identified in additional ALS patients and in HSP or other motor nerve 134 
disorder patients in other databases but, crucially, were not seen at all in any individuals in 135 
the control groups. Based on their strongly skewed distribution between patients and 136 
controls, we propose that these SARM1 GoF alleles are thus strong candidates for risk 137 
alleles in ALS and other motor nerve disorders and raises the possibility that other 138 




Identification of a cluster of ALS patient-specific SARM1 ARM domain coding variants 142 
in Project MinE data freeze 1 143 
Previous studies have shown that artificial missense mutations and in-frame deletions in the 144 
auto-inhibitory ARM domain of SARM1 are more likely to result in pro-degenerative GoF 145 
than disruption of its SAM multimerization domains or catalytic TIR domain, which instead is 146 
more likely to give rise to protective LoF (Gerdts et al., 2013; Summers et al., 2016; 147 
Essuman et al., 2017; Horsefield et al., 2019; Jiang et al., 2020; Sporny et al., 2020; 148 
Bratkowski et al., 2020; Figley et al., 2021; Shen et al., 2021). Therefore, if SARM1 149 
contributes to ALS pathogenesis, we predicted that there might be a relative paucity of 150 
naturally-occurring coding variation in the SAM and TIR domains and/or an enrichment of 151 
coding variation in the ARM domain among patients, with the opposite in unaffected 152 
individuals. 153 
 To explore this, we assessed the distribution of mostly rare SARM1 missense SNP and 154 
small, in-frame deletion alleles between cases and controls in Project MinE consortium data 155 
freeze 1 (DF1), a public database containing WGS data for 4,366 mostly sporadic ALS 156 
patients and 1,832 non-ALS controls (Project MinE ALS Sequencing Consortium, 2018; van 157 
der Spek et al., 2019). Even accounting for the fact that a proportion of the coding variation 158 
is likely to be functionally neutral, the distribution of alleles was notably skewed (Figure 1 159 
and Table 1). Specifically, of the 16 alleles encoding changes between amino acids 112 and 160 
385 of the SARM1 ARM domain, all are seen in patients, but only the two relatively more 161 
common alleles are also seen in controls, whereas the distribution of coding variation 162 
between patients and controls for the remainder of the gene is largely unremarkable, being 163 
much more proportional to the sizes of the patient and control groups. Based on this uneven 164 
distribution, we thus hypothesised that some of the patient-specific Project MinE DF1 ARM 165 
domain alleles are risk alleles for ALS through pro-degenerative GoF.  166 
 167 
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Several ALS patient-specific SARM1 ARM domain coding variants in Project MinE DF1 168 
increase NAD+ depletion in transfected HEK 293T cells 169 
We first tested the functional consequences of coding variation in the region spanning amino 170 
acids 112 to 385 of the SARM1 ARM domain by assessing the ability of variants to deplete 171 
NAD+ in transfected HEK 293T cells. We hypothesised that some of them confer a harmful, 172 
and thus potentially pathogenic NADase GoF, but established assay conditions able to 173 
detect either GoF or LoF of the exogenously-expressed SARM1 (Figure 2 - figure 174 
supplement 1A). Importantly, any contribution from endogenous SARM1 in these assays 175 
was expected to be negligible due to its comparatively very low level of expression in the 176 
HEK 293T cell clone used (Figure 2 - figure supplement 1B). 177 
 Under these conditions, NAD+ levels are approximately halved in cells expressing 178 
exogenous WT SARM1 (due to overexpression of a low constitutive NADase activity) but we 179 
observed a substantially greater lowering of NAD+ for six of the ALS-specific variants - 180 
L223P, 229-235 (alternatively named 226-232 - see Table 1 legend), 249-252, V331E, 181 
E340K and T385A SARM1 - suggestive of strong NADase GoF (Figure 2A). Smaller, but still 182 
statistically-significant lowering of NAD+ was also seen for a further three variants - V112I, 183 
A275V and A341V SARM1 - suggestive of more modest/moderate GoF. All other variants 184 
depleted NAD+ to a similar extent as WT SARM1. The variants that had the strongest effect 185 
on NAD+ levels also caused greater depletion of NADP+ and ATP than WT SARM1 (Figure 186 
2B and 2C), with NADP+ representing an alternative substrate of SARM1 glycohydrolase 187 
activity (Essuman et al., 2018; Horsefield et al., 2019; Wan et al., 2019) and ATP loss likely 188 
to be a lagging consequence of NAD+ loss.  189 
 Importantly, the lower level of NAD+ seen for some variants in these assays was not a 190 
result of greater variant overexpression. Instead, we found that the variants that caused the 191 
greatest NAD+ depletion are barely detectable by immunoblotting (Figure 2D). By using 192 
antibodies against either the C-terminal Flag tag or the N-terminus of SARM1, we can rule 193 
out any contribution of truncated forms of the variants (Figure 2 - figure supplement 2A). 194 
This indicates that enhanced NAD+ depletion is achieved by substantially lower levels of full-195 
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length versions of some of the variants and suggests very strong GoF. IRES-driven 196 
expression of ZsGreen (in a bicistronic cassette with SARM1) was also found to be 197 
substantially lower in cells with the greatest NAD+ depletion (Figure 2D). Crucially, 198 
fluorescence imaging suggested that this reflected suppressed ZsGreen expression within 199 
cells rather than reduced transfection efficiency (Figure 2E), which would anyhow be 200 
incompatible with almost complete NAD+ depletion if many cells remained untransfected. 201 
However, this appears to be consistent with a previous report showing that overexpression 202 
of (WT) SARM1 suppresses de novo synthesis of exogenous proteins in an NADase-203 
dependent manner (Izadifar et al., 2021). In support of this mechanism, we found that the 204 
cell permeable NAD+ precursor nicotinamde riboside (NR) allows higher levels of expression 205 
of both zsGreen and the putative strong NADase GoF SARM1 variants themselves, 206 
presumably by boosting NAD+ synthesis and thus delaying the point at which NAD+ 207 
becomes limiting for de novo protein synthesis as a result of enhanced SARM1 NADase 208 
activity (Figure 2 - figure supplement 2B and 2C). Even so, we cannot exclude reduced 209 
stability as also contributing to the low expression levels of these variants. 210 
 Previously, reduced cell viability has been reported in transfected HEK cells expressing 211 
active SARM1 mutants (Panneerselvam et al., 2012; Gerdts et al., 2013; Sporny et al., 2019, 212 
2020), but we did not see any obvious change in cell morphology suggestive of a loss of cell 213 
viability in our assays (Figure 2E), even when NAD+ was substantially depleted. While this 214 
probably partly reflects that we use a lower amount of SARM1 expression construct in our 215 
assays, we also found that SARM1 activity-dependent loss of viability of transfected HEK 216 
293T cells is very dependent on cell density, with the high cell densities we routinely use 217 
also conferring substantial protection (Figure 2 - figure supplement 3). 218 
  219 
Project MinE DF1 putative GoF SARM1 variants have very high constitutive NADase 220 
activity 221 
Our measurements of NAD+ levels in transfected HEK 293T cells indirectly pointed to 222 
variable degrees of NADase GoF for a number of the Project MinE patient-specific SARM1 223 
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ARM domain coding variants. Therefore, we next directly tested the NADase activity of 224 
purified recombinant WT and variant SARM1. Recombinant proteins were purified from 225 
transfected HEK 293T cell lysates by immunoprecipitation following NR supplementation of 226 
the HEK 293T cell medium to boost expression and maximise yield, particularly of the strong 227 
GoF variants (see above) (Figure 3 - figure supplement 1). 228 
 Constitutive (basal) NADase activity of the purified proteins in reactions containing just 229 
NAD+ was assayed first. We used 25 µM NAD+, which is close to the Km for the SARM1 230 
catalytic site (Essuman et al., 2018; Sporny et al., 2020; Angeletti et al., 2021) and obtained 231 
an NAD+ consumption rate for WT SARM1 (~1 mol/min/mol enzyme) comparable to that 232 
reported in a previous study (Zhao et al., 2019). Importantly, these assays confirmed the 233 
hypothesised NADase GoF for most of the variants that increased depletion of NAD+ in 234 
transfected HEK 293T cells, but in some cases their constitutive activity was unexpectedly 235 
high: rates for five of the patient-specific variants - L223P, 229-235, 249-252, V331E and 236 
E340K - were found to be up to 20 times higher than WT SARM1 and a sixth - T385A - 237 
around 10 times higher (Figure 3A). In fact, these very high per mol constitutive NADase 238 
activities are similar to that of SARM1 lacking the extreme N-terminus and auto-inhibitory 239 
ARM domain (SAM-TIR fragment, amino acids 409-724) (Figure 3B). 240 
 Of the three other variants that increased NAD+ depletion in transfected HEK 293T cells, 241 
V112I SARM1 has a rate a little more than twice as high as WT SARM1, whereas the 242 
activities of A275V and A341V SARM1 are not significantly raised (Figure 3A), although we 243 
cannot rule out subtle differences in the activities of the recombinant proteins compared to 244 
their activities in cells. Interestingly, the constitutive NADase rates calculated for P332Q and 245 
N337D, the variants present in both the patient and control groups, and R310H, a patient-246 





Project MinE DF1 SARM1 variants with high constitutive NADase activity are not 251 
further activated by NMN 252 
The NADase activity of full-length SARM1 can be induced by NMN (Zhao et al., 2019; Loreto 253 
et al., 2020; Figley et al., 2021), a nucleotide that plays a critical role in triggering axon 254 
degeneration (Di Stefano et al., 2015, 2017). Greater activation by NMN could thus 255 
represent an alternative pro-degenerative GoF mechanism. We therefore tested the 256 
recombinant SARM1 ARM domain coding variants for NMN-dependent triggering of their 257 
NADase activity. 258 
 We first assessed activation by 50 µM NMN. This is a higher level of NMN than would 259 
likely occur in neurons and/or axons, even after injury (Angeletti et al., 2021), and should 260 
thus promote robust SARM1 NADase activation in these assays. Under these conditions, 261 
the NADase activity of WT SARM1 roughly tripled but there was no clear increase for the six 262 
variants with very high constitutive activity (L223P, 229-235, 249-252, V331E, E340K and 263 
T385A SARM1) (Figure 3C). This mirrors a lack of NMN-responsiveness for the SAM-TIR 264 
fragment lacking the allosteric binding site in the auto-inhibitory ARM domain (Zhao et al., 265 
2019 and data not shown). 266 
 In contrast, with the exception of V112I SARM1, all the variants with a constitutive 267 
activity closer to that of WT SARM1 were found to be NMN-inducible to some extent, with 268 
most showing levels of inducibility similar to WT SARM1 (Figure 3C and Figure 3 - figure 269 
supplement 2A and 2C). P332Q SARM1, a more common variant equally abundant in ALS 270 
patients and controls, appears much more inducible than WT SARM1 (Figure 3 - figure 271 
supplement 2C), but this largely reflects its substantially lower constitutive activity with its 272 
NMN-activated rate being only marginally higher than that of WT SARM1 (Figure 3C and 273 
Figure 3 - figure supplement 2A). Indeed, none of the NMN-activated rates of any of the 274 
other NMN-responsive variants were significantly higher than that of WT SARM1, and for 275 
some (R244S, R310H and N337D SARM1) the activated rate was lower (Figure 3C and 276 
Figure 3 - figure supplement 2A). On the other hand, V112I SARM1, which has moderately 277 
raised constitutive NADase activity, instead showed no NMN-responsiveness and its activity 278 
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in the presence of 50 µM NMN is lower than the NMN-induced activity of WT SARM1 (Figure 279 
3 - figure supplement 2A). 280 
 Increased sensitivity to lower concentrations of NMN could represent an alternative pro-281 
degenerative GoF mechanism, so we next assessed triggering of NADase activity by 10 µM 282 
NMN (excluding the non-responsive strong GoF variants). This concentration of NMN is 283 
likely to be closer to the concentration in damaged neurons / axons (Angeletti et al., 2021) 284 
but is the lowest concentration that gives consistent activation of WT SARM1 in these in vitro 285 
assays. The increase in activity of WT SARM1 in the presence of 10 µM NMN was roughly 286 
half that seen with 50 µM NMN (in parallel assays) and all the ALS patient variants 287 
previously found to be responsive to 50 µM NMN showed a similar or even lower relative 288 
level of activation with 10 µM NMN (Figure 3D and Figure 3 - figure supplement 2B and 2D), 289 
apart from V112I SARM1 which again is not inducible (Figure 3D). As with 50 µM NMN, 10 290 
µM NMN induced P332Q SARM1 activity to a greater extent than that of WT SARM1 but its 291 
activated rate in the presence of 10 µM NMN in this case was below that of WT SARM1 292 
(Figure 3D and Figure 3 - figure supplement 2B and 2D). 293 
 Together, these NADase activity data indicate that six of the exclusively patient-294 
associated SARM1 ARM domain alleles in Project MinE DF1 encode variants with greatly 295 
enhanced constitutive activity comparable to that of the fully disinhibited SAM-TIR fragment, 296 
and one additional patient-associated variant showed more moderate constitutive NADase 297 
GoF. Surprisingly, however, no variants showed enhanced responsiveness to NMN from the 298 
normal basal level. Thus, the point mutations and small in-frame deletions that confer the 299 
strongest GoF mimic the effects of complete removal of ARM domain auto-inhibition. 300 
 301 
Identification of an additional ALS patient-associated strong GoF SARM1 variant in 302 
the Answer ALS project database. 303 
We next extended our search for putative ALS-associated SARM1 GoF alleles to the 304 
Answer ALS project database consisting of WGS data for 706 ALS patients and 92 matched 305 
controls (Rothstein, 2020). Some of the Project MinE DF1 variants were independently 306 
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found in this new, non-overlapping dataset, including one occurrence of the strong NADase 307 
GoF 229-235 SARM1 allele in a patient, but we also found three new patient-associated 308 
alleles and one new control-associated allele encoding changes within the ARM domain or 309 
just N-terminal to it (encompassing amino acids 29-397) (Figure 1 and Table 2). Three 310 
additional coding variants are also present in this expanded region in control subjects in 311 
Project MinE DF1 (Table 1). Therefore, given the precise N-terminal boundary of the ARM 312 
domain is not well-defined, we assessed the NADase function of all these previously 313 
untested coding variants from both databases, with the exception of Project MinE DF1 314 
frameshift variant L76fs that can reasonably be assumed to be a full LoF allele. 315 
 Using the same assays as for the original Project MinE variants, we identified patient-316 
associated Answer ALS variant, R267W SARM1, as an additional strong GoF, with robust 317 
NAD+-consuming activity in transfected HEK 293T cells combined with low expression 318 
(Figure 4A and 4B) and a constitutively high, non-inducible NADase activity equivalent to 319 
that of the strongest Project MinE GoF variants (Figure 4C and 4E). Interestingly, two of the 320 
control-associated variants, V88M SARM1 (Project MinE DF1) and A210V SARM1 (Answer 321 
ALS), also reduced NAD+ levels more than WT SARM1 in transfected HEK 293T cells 322 
(Figure 4A), but their constitutive activities in NADase assays were only modestly increased 323 
relative to WT SARM1 and far below the 10 times higher activity we define for strong GoF 324 
variants (Figure 4D). In addition, both show normal NMN-inducibility (Figure 4F). The 325 
remaining patient- and control-associated variants had properties similar to WT SARM1 or 326 
appeared to be modest LoF (Figure 4). 327 
 328 
Strong NADase GoF Δ229-235 SARM1 retains its GoF properties in complexes with 329 
WT SARM1. 330 
Given the very low levels of endogenous SARM1 in our HEK 293T cell line, our data so far 331 
will largely reflect the properties of each SARM1 variant in isolation. However, ALS patients 332 
heterozygous for SARM1 GoF alleles will express the SARM1 variant alongside WT 333 
SARM1. Therefore, to mimic heterozygosity, we co-expressed WT and strong GoF SARM1 334 
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in HEK 293T cells, using 229-235 SARM1 as a representative strong GoF variant as it is 335 
most frequently seen in patients. 336 
 We found that NAD+ depletion in HEK 293T cells co-transfected with equal amounts of 337 
WT and 229-235 SARM1 expression constructs was broadly similar to that in cells 338 
transfected with the 229-235 SARM1 construct alone (Figure 5A), although enzyme assays 339 
of the recombinant proteins are more effective at differentiating between moderate and high 340 
NADase GoF (see below). Expression of ZsGreen and SARM1 (both 229-235 and WT 341 
SARM1) was also strongly suppressed in both situations where 229-235 SARM1 is present 342 
in the transfected HEK 293T cells (Figure 5B), further supporting the model in which de novo 343 
synthesis of proteins is suppressed by enhanced SARM1 NADase activity. 344 
 SARM1 readily homo-multimerises in solution to form an octameric ring structure 345 
(Gerdts et al., 2013; Horsefield et al., 2019; Sporny et al., 2019; Bratkowski et al., 2020; 346 
Jiang et al., 2020; Sporny et al., 2020; Figley et al., 2021; Shen et al., 2021) and our finding 347 
that (Flag-tagged) 229-235 SARM1 efficiently co-immunoprecipitates with (HA-tagged) WT 348 
SARM1 from co-expressing cells is indicative that hetero-oligomers of WT and variant 349 
SARM1 are also readily formed (Figure 5C). Direct assaying of the NADase activity of 350 
hetero-oligomers revealed their constitutive NADase activity to be intermediate between that 351 
of each protein alone, but this still represents very strong GoF relative to WT SARM1 alone 352 
(Figure 5D). This is consistent with each protein retaining its own individual constitutive 353 
activity within the hetero-oligomers, although their lack of NMN-responsiveness suggests 354 
that WT SARM1 within the complexes may be altered in that respect (Figure 5E). 355 
 356 
Acute expression of strong GoF 229-235 SARM1 reduces viability of sympathetic 357 
neurons under stress conditions in an NADase-dependent manner. 358 
To test the effects of greatly enhanced constitutive activity in neurons, we used an 359 
established method involving microinjection of controlled amounts of expression constructs 360 
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into cultured sympathetic neurons from the superior cervical ganglion (SCG neurons), a 361 
neuronal subtype very amenable to this approach (Gilley & Loreto, 2020). 362 
 We first compared the effects of our representative strong GoF SARM1 variant, 229-363 
235 SARM1, with those of WT SARM1. We used wild-type SCG neurons for these 364 
experiments so that exogenous 229-235 SARM1 would be expressed alongside 365 
endogenous (WT) SARM1 in order to partially model neurons in individuals heterozygous for 366 
the 229-235 SARM1 allele. However, we minimised the amount of SARM1 expression 367 
vector injected to reduce possible artefacts of high expression, whilst still maintaining levels 368 
that are functionally relevant (Figure 6 - figure supplement 1), so the endogenous murine 369 
SARM1 will likely be in excess of the exogenous SARM1 in these experiments. A DsRed 370 
expression construct was co-injected to improve visualisation of the targeted neurons and 371 
their neurites (co-expression of ZsGreen from the SARM1 construct being insufficient under 372 
these conditions) and we consistently saw substantially fewer DsRed labelled neurons 24 h 373 
after injection with the 229-235 SARM1 construct compared to the WT SARM1 construct or 374 
empty vector (Figure 6A and 6B and Figure 6 - figure supplement 2A). The intensity of 375 
DsRed in the few labelled 229-235 SARM1 neurons that were present was also greatly 376 
reduced. We found that NR supplementation boosted DsRed expression and visualisation of 377 
the 229-235 SARM1 neurons (Figure 6A and 6B) suggesting that strong NADase GoF 378 
suppresses DsRed expression in neurons in the same way that it suppresses co-expression 379 
of ZsGreen in transfected HEK 293T cells (Figure 2D and 2E and Figure 2 - figure 380 
supplement 2B and 2C), although a separate effect on neuronal viability also cannot be 381 
ruled out. 382 
 The greatly improved visualisation of neurons injected with the 229-235 SARM1 383 
expression construct in the presence of NR allowed us to next assess their response to 384 
various stresses. Intriguingly, we found that the modest stresses associated with changes in 385 
culture conditions as a result of media change, even to new NR-containing medium, was 386 
sufficient to trigger a substantial loss of the 229-235 SARM1 neurons (compared to not 387 
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changing media), and further manipulations designed to reduce NAD+ biosynthesis - 388 
removal of NR, or a combination of NR removal and incubation with NAMPT inhibitor FK866 389 
to block the rate-limiting step in the NAD+ salvage pathway - caused additional, incremental 390 
decreases in cell survival (Figure 6C and 6D). In contrast, neurons injected with the WT 391 
SARM1 construct or empty vector were not substantially affected by any of the 392 
manipulations (Figure 6C and 6D and Figure 6 - figure supplement 2B). Importantly, we 393 
could not differentiate the timing of cell death and neurite degeneration in these 394 
experiments, suggesting either that the primary effect is on neuronal viability or that separate 395 
cell body and neurite death mechanisms occur simultaneously. 396 
 In order to assess whether NADase activity is required for the pro-death effects of 229-397 
235 SARM1, we combined the 229-235 deletion with the E642A NADase-inactivating 398 
mutation (Essuman et al., 2017). We found that double mutant 229-235/E642A SARM1, 399 
like single mutant E642A SARM1, has little or no effect on NAD+ levels in transfected HEK 400 
293T cells (Figure 7A), consistent with a lack of NADase activity. We also saw much more 401 
robust expression of 229-235/E642A SARM1 and co-expressed ZsGreen compared to 402 
cells expressing 229-235 SARM1 (Figure 7B). This further supports a correlation between 403 
SARM1 NADase activity and de novo protein synthesis. Crucially, in contrast to 229-235 404 
SARM1, SCG neurons injected with a 229-235/E642A SARM1 construct were easily 405 
identified, even in the absence of NR supplementation, and were not sensitive to combined 406 
NR removal and incubation with NAMPT inhibitor FK866 (after being cultured in the 407 
presence of NR) (Figure 7C and 7D). Therefore, NADase activity is required for the pro-408 
death effects of 229-235 SARM1 in this assay. 409 
 410 
Evidence for enrichment of strong GoF SARM1 variants in ALS, HSP and other motor 411 
nerve disorder patients. 412 
Among the total of 23 SARM1 ARM domain and other N-terminal coding variants seen in 413 
patients and controls in the Project MinE DF1 and Answer ALS databases, we have 414 
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identified a group of seven of the exclusively patient-associated variants - L223P, 229-235, 415 
249-252, R267W, V331E, E340K and T385A SARM1 - as having very strong constitutive 416 
NADase GoF, with each being 10-20 times more active than WT SARM1. No other variants 417 
came close to this level, although V112I (in a patient) and V88M and A210V (in controls) 418 
showed more modest increases in constitutive activity to 1.7-2.2 times that of WT SARM1. 419 
Therefore, within these datasets, strong NADase GoF SARM1 alleles are only seen in 420 
patients and never in controls. This is consistent with our hypothesis that strong SARM1 421 
NADase GoF is a risk factor for ALS. 422 
 In order to investigate this association in more depth, we assessed whether any of the 423 
23 variants assessed for function in this study appear in other relevant cohorts, including 424 
cohorts containing patients with HSP and other motor nerve disorders. If the association is 425 
robust, then the rare, strong GoF variant alleles identified here should remain enriched in 426 
patients and underrepresented in control individuals, while variants with properties more like 427 
WT SARM1 would not show consistent association with either group. We identified the 428 
following additional datasets for this purpose: case and control samples in Project MinE data 429 
freeze 2 (DF2) that were not part of DF1; samples from motor nerve disorder cases and 430 
selected control groups (see Materials and Methods) from the GENESIS project (Gonzalez 431 
et al., 2015) and a UCL rare disease (neurology) dataset; cases and controls from an HSP 432 
study; and the Lothian birth cohort (LBC) (http://www.lothianbirthcohort.ed.ac.uk) as an 433 
additional aged control cohort. Among these datasets, four additional cases are 434 
heterozygous for one of the strong GoF alleles (two ALS cases, one HSP case and one 435 
upper and lower motor nerve disorder case) whereas no controls in any dataset were 436 
identified as carriers of these alleles (Table 3). Therefore, in total, 13 of the 11,117 patients 437 
in the combined datasets are heterozygous for a strong GoF SARM1 allele (13 out of 22,234 438 
alleles), with no carriers among 10,402 controls (0 out of 20,804 alleles) (Table 3). In 439 
contrast, a number of the other alleles encoding variants with properties more similar to WT 440 
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SARM1, including some of those previously only associated with cases in Project MinE DF1 441 
and Answer ALS, were present in both cases and controls in the new datasets (Table 3). 442 
 We next performed statistical analyses on aggregated data from all the datasets to test 443 
the strength of the association specifically between SARM1 GoF and motor nerve disorders. 444 
Crucially, burden testing of the group of seven strong GoF variant alleles together in the 445 
combined datasets revealed a highly significant association with disease (burden test and 446 
SKAT-O p=0.00017) whereas there was no clear association with disease when considering 447 
all the other alleles as a group (burden test p=0.47, SKAT-O p=0.61). In addition, there is a 448 
greater than four times enrichment of the strong GoF alleles among our aggregated patient 449 
cohorts compared to European (non-Finnish) non-neuro samples from gnomAD v3.1.1 450 
(Table 4 - MAF of 0.00058 versus 0.00014) and, despite the presence of a few carriers of 451 
strong GoF SARM1 alleles in this gnomAD cohort and the uncertainty regarding their health 452 
status (see Table 4 legend), their inclusion as additional controls in the statistical tests 453 
actually strengthens the association between the SARM1 strong GoF alleles and disease 454 
(burden test p=0.000025, SKAT-O p=0.000057). Notably, disease-association also remains 455 
even when the patient-associated V112I SARM1 allele and control-associated V88M and 456 
A210V SARM1 alleles, encoding more modest GoF variants, are grouped with the strong 457 
GoF alleles (burden test p=0.0042, SKAT-O p=0.0021 excluding gnomAD samples, and 458 
burden test p=0.000047, SKAT-O p=0.00019 including gnomAD samples). Together, these 459 
tests suggest that SARM1 ARM domain coding variation that results in constitutive NADase 460 
hyperactivation is very strongly associated with ALS and other motor nerve disorders. 461 
Individual-level data were not available for all datasets to identify covariates to correct for 462 
population stratification, but the use of broadly matched datasets to minimise the effect of 463 
population variation (see Materials and Methods) means that results are likely to reflect true 464 
disease-associated genetic variation. 465 
 466 
Phenotypic heterogeneity and variable age-of-onset in patients with SARM1 GoF 467 
alleles 468 
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Finally, we collated clinical information for all the individuals in our combined datasets that 469 
are heterozygous for the SARM1 alleles encoding the strong GoF variants identified in this 470 
study (Table 5). Information is also provided for one additional ALS case heterozygous for 471 
the 229-235 variant SARM1 allele from an independent source, and for the one individual 472 
heterozygous for the allele encoding moderate GoF V112I SARM1 for comparison. 473 
Intriguingly, as well as confirming there is no patient duplication among the group, this 474 
reveals a broad range of clinical presentation and a highly variable age-of-onset among the 475 
cases, with no obvious heritability. 476 
 The lack of any clear and consistent trend in disease severity probably indicates that 477 
SARM1 GoF is not the only driver of disease in some or all of these cases. In this respect it 478 
is notable that two of the ALS cases are also heterozygous for I114T (previously reported as 479 
I113T) SOD1 and L17P FIG4 variant alleles that have previously been linked to ALS or 480 
recessive Charcot-Marie-Tooth disease type 4J (CMT4J). Given that the I114T SOD1 allele 481 
shows incomplete penetrance (Lopate et al., 2010) and the L17P FIG4 allele has previously 482 
only been associated with CMT4J in combination with a null allele (Nicholson et al., 2011), it 483 
raises the possibility that an interaction with the SARM1 GoF alleles is critical for 484 
pathogenesis in these ALS cases. Therefore, an interaction between SARM1 GoF alleles 485 
and other risk alleles may enhance phenotypic expressivity and underlie some of the 486 




Here, we have identified seven disease-associated SARM1 alleles in patients with ALS or 490 
other motor nerve disorders that encode missense or in-frame microdeletion variants with 491 
constitutive NADase activity as much as ten to twenty times higher than that of WT SARM1. 492 
This level of activity is comparable to that of SARM1 lacking any auto-inhibition and is 493 
substantially higher than the activity of WT SARM1 in the presence of NMN, a natural 494 
activator of SARM1 NADase during injury-induced and other related forms of axon 495 
degeneration. Although co-expression experiments suggest that the NADase activity of 496 
hetero-oligomers of WT and strong NADase GoF SARM1 will be around half that of homo-497 
oligomers of strong GoF SARM1 alone, this still represents a considerable increase in 498 
activity. Consistent with this, acute expression of strong NADase GoF SARM1 alongside WT 499 
SARM1 in primary cultured neurons is sufficient to promote robust NADase-dependent cell 500 
death (and simultaneous or secondary axon degeneration) in response to otherwise non-501 
harmful mild stress. Crucially, these seven strong GoF alleles are enriched in the motor 502 
nerve disorder cohorts studied compared to control groups or the wider population 503 
implicating constitutively hyperactivated SARM1 as a risk factor for these diseases. 504 
 Despite the robust association between SARM1 strong GoF variants and disease in 505 
these cohorts, the proportion of motor nerve disorder cases that are heterozygous for the 506 
strong GoF alleles identified here is only 0.12%. However, other ALS patient-associated 507 
SARM1 alleles encoding variants with predicted strong NADase GoF have been identified 508 
concurrently with this study (Bloom et al., 2021), and there are many other ARM domain 509 
variant alleles among our extended datasets that remain untested and could, therefore, 510 
include additional GoF alleles. The real percentage may thus be higher. Furthermore, in light 511 
of this association, we expect that other SARM1 GoF and/or activation mechanisms will also 512 
be found to play a key role in motor nerve disorders. For example, the GWAS association 513 
between a SARM1 intragenic SNP and ALS (Fogh et al., 2014; van Rheenen et al., 2016) 514 
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could be driven by increased SARM1 expression as a result of more common variants which 515 
impact transcriptional regulation of the SARM1 gene. Reduced expression of Stathmin-2 516 
(STMN2, also known as SCG10), which potentiates programmed axon degeneration (Shin 517 
et al., 2012), has also been linked to the disease via a mechanism that is expected to 518 
involve aberrant SARM1 activation. Specifically, STMN2 depletion increases the vulnerability 519 
of ALS patient iPSC-derived neurons (Klim et al., 2019; Melamed et al., 2019), and a non-520 
coding STMN2 variant that influences gene expression has recently also been associated 521 
with increased risk of sporadic disease (Theunissen et al., 2021). An age-related decline in 522 
NMNAT2 expression and/or delivery to axons or exposure to environmental toxins could 523 
also result in aberrant SARM1 activation and increased risk of disease (Milde et al., 2015; 524 
Loreto et al., 2020; Wu et al., 2021). 525 
 The association between motor nerve disorders and functionally-confirmed strong GoF 526 
variants of SARM1 we report here is highly significant at the individual gene level and 527 
contrasts with the absence of disease association for neighbouring variants with properties 528 
more comparable to WT SARM1 (thereby representing good controls for testing our 529 
hypothesis). Thus, unlike a conventional gene burden analysis, it is the functional 530 
consequence of each variant, rather than its location, that correlates with disease. The low 531 
allele frequency of the GoF variants, even after their enrichment in ALS, means there is 532 
insufficient power to show genome-wide significance, although the lead SNP in an ALS 533 
GWAS study, rs35714695, which is far more common and hence does show genome-wide 534 
significance, is located only 8.3-11.4 kb from each of these strong GoF variants within the 535 
same ~200 kb linkage disequilibrium block (Fogh et al., 2014; van Rheenen et al., 2016). 536 
Although these are essentially independent observations, as it is not feasible to confirm 537 
linkage disequilibrium between such rare SNPs and rs35714695, they separately support 538 
the notion that SARM1 contributes to ALS. Hypothesis-driven studies such as this one are, 539 
of course, not unbiased in the way that GWAS is, but instead depend substantially on the 540 
strength of the hypothesis and the availability of clear functional data to support it. However, 541 
where these are both provided they have a vital role to play in complementing GWAS 542 
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studies by closing the large heritability gap in ALS and other disorders (Van Damme, 2018), 543 
since genome wide significance for genuinely pathogenic, but very rare alleles, may not be 544 
an achievable goal. The current study also illustrates the importance of publicly available 545 
datasets such as Project MinE in making such work possible. 546 
 Among the SARM1 variants tested for function in this study, the seven with strong 547 
NADase GoF can be clearly differentiated from the rest. However, we cannot rule out that a 548 
more modest increase in constitutive NADase GoF, directly demonstrated for some variants 549 
in NADase assays of recombinant protein (V88M, V112I and A210V SARM1) or possibly 550 
implied for others based on their ability to modestly enhance NAD+ loss in HEK cells (A275V 551 
and A341V SARM1), might also have biologically-relevant consequences. It was also 552 
surprising to us that raised constitutive activity was the only GoF effect we identified among 553 
the ALS patient-associated SARM1 alleles, with no evidence of enhanced triggering by NMN 554 
from a normal basal level. While our recombinant protein assays provide a useful insight into 555 
the relative NMN-responsiveness of the different variants, and can clearly identify reduced 556 
NMN sensitivity, it is possible that some GoF relating to enhanced inducibility may not yet 557 
have been identified and that this could contribute to pathogenesis in some patients. 558 
 Recently, substantial progress has been made into elucidating the mechanism of auto-559 
inhibition of SARM1 NADase activity by the ARM domain (Jiang et al., 2020; Sporny et al., 560 
2020; Shen et al., 2021) and the strong GoF variants identified here could represent useful 561 
tools for further understanding. Given their vastly higher activities relative to NMN-activated 562 
WT SARM1, it seems unlikely that the amino acid changes in the strong GoF variants simply 563 
mimic the effects of NMN binding and/or block NAD+ binding in the allosteric site in the ARM 564 
domain and, notably, there is little direct overlap with residues that appear to be critical for 565 
NAD+/NMN interactions (Figley et al., 2021). Instead, constitutive activities similar that of the 566 
SAM-TIR fragment of SARM1 lacking the entire auto-inhibitory ARM domain suggest that 567 
the amino acid changes probably cause more profound structural changes that disrupt 568 
inhibitory interaction between the ARM and TIR domains completely. This would also explain 569 
the complete unresponsiveness of the variants to NMN. Consistent with this, some of the 570 
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changes in the strong GoF variants involve residues located at an ARM-TIR interface (R249 571 
and E252), an ARM-SAM interface (V331) or an ARM-ARM interface (T385) (Shen et al., 572 
2021). 573 
 Given the potent pro-death effect of constitutively hyperactivated SARM1 in primary 574 
neuronal cultures, the heterogeneous clinical presentation of motor nerve disorder patients 575 
with strong GoF SARM1 alleles is surprising. In fact, that they survive at all with such high 576 
constitutive SARM1 NADase activity is, in itself, unexpected given that our data indicate that 577 
WT SARM1 in the presence of NMN is less active than hetero-oligomers of WT and strong 578 
GoF SARM1 but is still predicted to be responsible for the early lethality in both mice and 579 
humans lacking functional NMNAT2 (Gilley et al., 2013, 2015; Lukacs et al., 2019). We 580 
therefore propose that chronic, physiological expression of constitutively hyperactivated 581 
SARM1 specifically triggers compensatory responses during development to limit its impact. 582 
Suppressed expression of SARM1 itself, as seen in transfected HEK 293T cells, is one 583 
possible compensatory change that could restrict NADase activity in vivo, although this 584 
seems to be a direct consequence of acute and extensive SARM1-dependent depletion of 585 
NAD+ (and/or ATP) resulting in suppression of de novo protein synthesis and it is hard to 586 
imagine long-term neuron survival under these conditions. Intriguingly, differential responses 587 
to constitutive or acute silencing of a single Nmnat2 allele is also suggestive of 588 
compensatory changes in the chronic condition (Gilley et al., 2013) and it is tempting to 589 
speculate that they might be related. 590 
 It will also be important to firmly establish the extent of the penetrance of the GoF alleles 591 
identified here and whether any show a familial association with motor nerve disorders. 592 
However, their presence in sporadic cases, and co-occurrence with partially-penetrant 593 
disease variants of other genes in some patients, suggest that they have to interact with 594 
other risk factors to reveal their pathogenicity. Future human genetics studies should help to 595 
address these possible associations. There are also a number of drug development 596 
programmes and other avenues of therapeutic intervention targeting SARM1 currently being 597 
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pursued (Geisler et al., 2019; Hughes et al., 2021; Bosanac et al., 2021) and individuals with 598 
SARM1 GoF alleles would thus be ideal test subjects if other requirements are met. 599 
 In summary, we report seven rare SARM1 alleles encoding variants with constitutive 600 
NADase activity much higher than NMN-activated wild-type SARM1, and broadly 601 
comparable to that of completely uninhibited SARM1, that show clear association with ALS 602 
and other motor nerve disorders in a small percentage of patients. There is phenotypic 603 
heterogeneity in the clinical presentation, reminiscent of other ALS disease genes, and this 604 
raises intriguing questions both about the potential pathogenic role of constitutively 605 
hyperactive SARM1 and about why their extraordinarily high NADase activity is not 606 
immediately lethal. Association of function-altering coding variants also supports the notion 607 
that SARM1 has a wider contribution to ALS. While further replication in other cohorts is 608 
important, along with direct evidence that SARM1 activity is necessary for pathogenesis to 609 
firmly establish causation, the results presented here strongly implicate SARM1 as a risk 610 




MATERIALS AND METHODS 614 
 615 
Constructs and reagents 616 
The bicistronic pLVX-IRES-ZsGreen1 vector (Clontech / Takara Bio 632187) was the 617 
backbone for all SARM1 expression constructs used in this study, unless stated otherwise. 618 
SARM1 and ZsGreen(1) are co-expressed from a bicistronic mRNA transcript under the 619 
control of the CMV promoter. The complete open reading frame (ORF) of the canonical 724 620 
amino acid human SARM1 protein was cloned into the first cistron between the EcoRI and 621 
SpeI restriction sites. An in-frame Flag tag followed by a stop codon were introduced 622 
between the XbaI and BamHI restriction sites immediately 3' to SARM1 ORF at the C-623 
terminus. The expressed SARM1 thus possesses a C-terminal Flag (after a 4 amino acid 624 
linker). ZsGreen occupies the second cistron and undergoes IRES-driven translation. For 625 
experiments in Figure 6 - figure supplement 1, untagged SARM1 was expressed from a 626 
pCMV-Tag4A vector backbone (Agilent Technologies) with the 724 amnio acid ORF, 627 
including a consensus Kozak sequence immediately 5' to the ATG codon and a stop codon 628 
at the 3' end of the ORF, cloned between the BamHI and XhoI restriction sites of the multiple 629 
cloning site. Point mutations were introduced into constructs by QuikChangeII site-directed 630 
mutagenesis (Stratagene) and microdeletions were introduced using overlap extension PCR 631 
(J. Lee et al., 2010). The presence of the mutations and absence of other PCR errors was 632 
confirmed by DNA sequencing (Department of Biochemistry, University of Cambridge). 633 
pDsRed2-N1 (Clontech) was used for expression of variant Discosoma red fluorescent 634 
protein (DsRed) to label microinjected neurons and their neurites. 635 
 PBS without calcium and magnesium (Merck) was used throughout, unless stated 636 
otherwise. NAD+ and NMN (both Merck) were dissolved in water and stored frozen as 637 
concentrated stocks. Nicotinamide riboside (NR) was prepared as a 100 mM stock from Tru 638 
Niagen® capsules by dissolving the contents in PBS and passing through a 0.22 µm filter. 639 





Cell lines and transfection  644 
Human embryonic kidney (HEK) 293T cells (clone 17, [HEK 293T/17]) were obtained from 645 
the American Type Culture Collection (ATCC, CRL-11268, RRID:CVCL_1926) and had 646 
been authenticated by STR profiling. Mycoplasma contamination was not detected. Cells 647 
were grown in DMEM with 4,500 mg/L glucose and 110 mg/L sodium pyruvate (PAA), 648 
supplemented with 2 mM glutamine, 1% penicillin/streptomycin (both Invitrogen), and 10% 649 
fetal bovine serum (PAA). Cells at 50-70% confluence were transfected with expression 650 
constructs (as described in the text / figure legends) using Lipofectamine 2000 reagent 651 
(Invitrogen) according to the manufacturer’s instructions. Amounts of DNA constructs 652 
transfected are described in the figure legends. 653 
 654 
Measurements of nucleotide levels in transfected HEK 293T cell extracts 655 
Transfected HEK 293T cells (from individual wells of 24-well plates) were collected and 656 
washed in ice-cold PBS 24 h after transfection and lysed in ice-cold KHM buffer (110 mM 657 
potassium acetate, 20 mM HEPES pH 7.4, 2 mM MgCl2, 0.1 mM digitonin) containing 658 
cOmplete™, Mini, EDTA-free protease inhibitor cocktail (Roche). Efficient lysis with KHM 659 
buffer required an initial trituration by pipetting and intermittent vortexing over a 10 min 660 
incubation on ice. Lysates were centrifuged for 5 min at 3000 rpm in a microfuge at 4C to 661 
pellet insoluble material, and supernatants were then collected on ice and diluted to 0.5 662 
µg/µl in cold KHM buffer after protein concentrations had been determined using the Pierce 663 
BCA assay (Thermo Fisher Scientific). The NAD/NADH-Glo™ and NADP/NADPH-Glo™ 664 
assays (Promega) were used to measure NAD+ and NADP+ in extracts. First, 25 µl of each 665 
extract was mixed with 12.5 µl 0.4M HCl and heated to 60C for 15 min to degrade NADH 666 
and NADPH before being allowed to cool to room temperature (RT) for 10 min. Reactions 667 
were then neutralised by adding 12.5 µl 0.5 M Tris base and 10 µl of each neutralised 668 
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reaction was mixed with 10 µl of the relevant detection reagent on ice in wells of a 384-well 669 
white polystyrene microplate (Corning). Once all reactions had been set up the plate was 670 
moved to a GloMax® Explorer plate reader (Promega) and incubated for 40 min at 25C 671 
before reading for luminescence. The CellTiter-Glo® assay (Promega) was used to measure 672 
ATP in extracts. Here, 10 µl of extract was mixed directly with 10 µl of assay reagent on ice 673 
in wells of a 384-well white polystyrene microplate. Luminescence was then read after 10 674 
min at 25C using a GloMax® Explorer plate reader. Concentrations of nucleotides were 675 
determined from standard curves generated from dilution series of the relevant nucleotides 676 
and then calculated as proportions of the amount in extracts from cells transfected in parallel 677 
with empty vector. 678 
 679 
Immunoprecipitation of recombinant SARM1 from HEK 293T cells 680 
Recombinant, C-terminal Flag-tagged or HA-tagged human SARM1 (WT or variant) was 681 
purified from HEK 293T cells by immunoprecipitation. HEK 293T cells in 10 cm and 6 cm 682 
dishes and individual wells of a 6 cm dish were respectively transfected with 24 µg, 10 µg 683 
and 4 µg of SARM1 expression construct. Media was supplemented with 2 mM NR at the 684 
time of transfection. Cells were lysed in KHM buffer as for the measurements of nucleotide 685 
levels in transfected HEK 293T cells (see above) but extracts were instead diluted to 1 µg/µl 686 
in cold KHM buffer after determining protein concentration. For immunoprecipitation, extracts 687 
were incubated overnight at 4°C with rotation with 20 µg/ml mouse ANTI-FLAG® M2 688 
monoclonal antibody (Sigma-Aldrich F3165, RRID:AB_259529) or 2 µg/ml mouse anti-HA 689 
monoclonal antibody, clone 12CA5 (Sigma-Aldrich 11583816001, RRID:AB_514505) and 50 690 
µl/ml of pre-washed Pierce magnetic protein A/G beads (Thermo Fisher Scientific). For co-691 
immunoprecipitations, beads were collected on a magnetic rack and washed 3x with KHM 692 
buffer and 1x with PBS (with protease inhibitors) and then resuspended in PBS containing 1 693 
µg/µl BSA. Beads were resuspended in 150 µl per ml of the original immunoprecipitation 694 
volume for normal yield proteins, or 25-50 µl for low yield proteins. Inclusion of BSA in the 695 
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re-suspension buffer allowed samples to be frozen without substantial loss of SARM1 696 
activity (activity is almost completely lost after one freeze/thaw cycle without its inclusion). 697 
The concentrations of SARM1 proteins in the bead suspension were determined by 698 
comparison to a standard curve generated from a dilution series of recombinant SARM1 of 699 
known concentration (purified from insect cells) after detection by immunoblotting using a 700 
rabbit polyclonal antibody raised against the SAM domains of human SARM1 (both kindly 701 
provided by AstraZeneca).  702 
 Of particular note, the use of KHM lysis buffer is critical for subsequent assaying of the 703 
NADase activity of the purified SARM1 protein. Harsher lysis buffers with high 704 
concentrations of strong detergents (e.g., RIPA-based buffers) themselves cause substantial 705 
activation of SARM1 NADase and a loss of responsiveness to NMN. 706 
 707 
NADase assays of recombinant purified SARM1 708 
A series of test assays were first performed to define appropriate concentrations of 709 
immunoprecipitated SARM1 proteins and the earliest, reliable assay timepoints to obtain 710 
rates as close as possible to the maximal rate under the various reaction conditions used. 711 
Optimised reaction conditions were as follows: 25 µl reactions (overall 1x PBS) contained 1 712 
ng/µl SARM1 protein for strong GoF variants (L223P, 229-235, 249-252, V331E, E340K 713 
and T385A) or SAM-TIR fragment, or 5 ng/µl of WT SARM1 and other variants, together with 714 
25 µM NAD+ ± 10 µM or 50 µM NMN. Reactions were kept on ice until all had been set up. 715 
All reactions were performed with the recombinant SARM1 still attached to beads as 716 
inefficient elution severely restricted the yield of the poorly-expressed GoF variants. Bead 717 
suspensions were thoroughly mixed prior to addition to the reactions. Constitutive (basal) 718 
NAD+ consumption was measured from reactions containing just NAD+ as the difference 719 
between starting levels (0 h) and levels remaining after a 1 h (for strong GoF variants) or 2 h 720 
(for all other variants) incubation at 25C. NAD+ consumption in the presence of NMN (both 721 
10 µM and 50 µM) was calculated after a 1 h incubation for all variants. Reactions were 722 
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each mixed once mid-way through the incubation period to resuspend the beads. To 723 
measure NAD+ using the NAD/NADH-Glo™ assay, 5 µl aliquots of the reaction were 724 
removed immediately after setting up (whilst still on ice), to obtain precise starting levels in 725 
individual reactions, and after the defined times listed above. Aliquots were then mixed with 726 
2.5 µl of 0.4 M HCl, to stop the reaction, and neutralised by mixing with 2.5 µl 0.5 M Tris 727 
base after 10 mins. To bring NAD+ concentrations down to the linear range of the 728 
NAD/NADH-Glo™assay, neutralised samples were subsequently diluted 1 in 50 in a buffer 729 
consisting of 50% PBS, 25% 0.4 M HCL, 25% 0.5 M Tris base. 10 µl of the diluted sample 730 
was then mixed with 10 µl of detection reagent on ice in wells of a 384-well white 731 
polystyrene microplate (Corning). Once all reactions had been set up the plate was moved 732 
to a GloMax® Explorer plate reader (Promega) and incubated for 40 min at 25C before 733 
reading for luminescence. NAD+ concentrations were determined from standard curves (as 734 
above). NAD+ consumption rates were converted to mol consumed per min per mol of 735 
SARM1 protein (mol/min/mol SARM1). This allows a direct comparison of rates between full-736 
length SARM1 and the SAM-TIR fragment. Individual data points for each separate protein 737 
preparation are the means of two technical replicates in most cases. Non-specific activity on 738 
bead/antibody complexes in control immunoprecipitations (from HEK 293T cells transfected 739 
with empty vector) was negligible at less than 0.5% of the constitutive NAD+ consumption 740 
seen for WT SARM1 (average of n=4 assays). 741 
 742 
Immunoblotting 743 
Protein extracts from transfected HEK 293T cells used for nucleotide measurements (0.5 µg 744 
protein/µl, see above) were diluted 1 in 2 with 2x SDS-PAGE loading buffer, and bead 745 
suspensions of immunoprecipitated recombinant SARM1 proteins were diluted 1 in 16 for 746 
immunoblotting. Samples were incubated at 100C for 3 mins and 10 µl of sample per lane 747 
resolved on 4-20% gradient gels (Bio-Rad) before being transferred to Immobilon-P 748 
membrane (Millipore). Blots were blocked in TBS (20 mM Tris p.H. 8.3, 150 mM NaCl) 749 
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containing 5% skim milk powder for 30 mins at RT before being incubated overnight at 4C 750 
with primary antibody in TBS containing 0.05% Tween-20 (Merck) (TBST) and 5% milk. After 751 
3x 10 min washes in TBST, blots were incubated for 1-2 h at RT with appropriate HRP-752 
conjugated secondary antibodies (diluted 1 in 3,000, Bio-Rad) in TBST with 5% milk. After 753 
3x 10 min washes in TBST and one rinse in TBS, blots were incubated with Pierce™ ECL 754 
Western Blotting Substrate or SuperSignal™ West Dura Extended Duration Substrate (both 755 
Thermo Fisher Scientific) and imaged using an Alliance chemiluminescence imaging system 756 
(UVITEC Cambridge). Relative band intensities on captured digital images were determined 757 
from areas under histogram peaks using Fiji software (http:fiji.sc).  758 
 The following primary antibodies were used: mouse ANTI-FLAG® M2 monoclonal 759 
antibody (Sigma-Aldrich F3165, RRID:AB_259529, 2 µg/ml as standard or 0.5 µg/ml for 760 
probing immunoblots of co-immunoprecipitations), mouse anti-ZsGreen1 monoclonal 761 
antibody, clone OTI2C2 (OriGene TA180002, RRID:AB_2622267, 1 in 1,000), mouse anti-762 
GAPDH monoclonal antibody, clone 6C5 (Abcam ab8245, RRID:AB_2107448, 1 in 2,000), 763 
mouse anti-HA monoclonal antibody, clone 12CA5 (Sigma-Aldrich 11583816001, 764 
RRID:AB_514505, 0.2 µg/ml as standard or 0.05 µg/ml for immunoblots of co-765 
immunoprecipitations), a rabbit polyclonal antibody raised against the SAM domains of 766 
human SARM1 (kindly provided by AstraZeneca, 1 in 2,000) and a mouse anti-SARM1 767 
monoclonal antibody (Chen et al., 2011) (1 in 2,000). 768 
 769 
Primary SCG neuron cultures and microinjection 770 
SCG neuron cultures were prepared from wild-type P1-P3 mouse pups (C57BL/6J, 771 
RRID:IMSR_JAX:000664), or Sarm1-/- P1-P3 pups (RRID:MGI:3765957) for Figure 6 - 772 
Figure Supplement 1 only, and were microinjected following established protocols (Gilley & 773 
Loreto, 2020). Mice were used in accordance with the Home Office Animal Scientific 774 
Procedures Act (ASPA), 1986 under project licence P98A03BF9. Dissected SCG ganglia 775 
were incubated at 37C for 20 min in 0.025% trypsin (Sigma) dissolved in PBS followed by 776 
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20 min in 0.2% collagenase type II (Gibco) in PBS (with calcium and magnesium). After, 777 
ganglia were gently triturated using a pipette tip in SCG culture medium comprising 778 
Dulbecco's Modified Eagle's Medium (DMEM) (4500 mg/L glucose and 110 mg/L sodium 779 
pyruvate, Sigma) supplemented with 2 mM glutamine (Invitrogen), 1% penicillin/streptomycin 780 
(Invitrogen), 10% fetal bovine serum (Sigma), 2 µg/ml aphidicolin (Calbiochem), and 100 781 
ng/ml 7S NGF (Invitrogen). After a 1-2 h pre-plating stage to remove non-neuronal cells, 782 
dissociated neurons were plated in a small laminin-coated area on ibidi µ-dishes pre-coated 783 
with poly-L-lysine (Thistle Scientific). Cultures were maintained in SCG medium, which was 784 
changed every 2-3 days, and were injected after 5-7 days. The inclusion of aphidicolin in the 785 
medium suppressed growth and proliferation of any non-neuronal cells. 786 
 SCG neurons were microinjected using a Zeiss Axiovert 200 microscope with an 787 
Eppendorf 5171 transjector and 5246 micromanipulator system and Eppendorf Femtotips. 788 
Expression constructs were diluted in 0.5x PBS and cleared by spinning through a Spin-X 789 
filter (Costar). The mix was injected into the nuclei of SCG neurons. The concentrations of 790 
expression constructs in the injection mix are listed in figure legends. 40-45 neurons were 791 
injected per dish. Although ZsGreen is co-expressed from the SARM1 vector used in these 792 
studies, restricting the amount of vector injected to limit SARM1 expression meant that the 793 
resulting ZsGreen expression was itself not sufficient for clear visualisation of injected 794 
neurons and their neurites. For the purposes of visualisation we thus had to co-inject a 795 
DsRed expression construct at a higher concentration. 796 
 797 
Imaging 798 
Fluorescence and phase contrast images of transfected HEK 293T cells and injected SCG 799 
neurons were acquired with a Leica DFC365FX fluorescence monochrome camera attached 800 
to a Leica DMi8 inverted fluorescence microscope using 10x and 20x objectives.  801 
 802 
Database resources 803 
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The different datasets used in this study are annotated to different genome builds, either 804 
Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19 (for Project 805 
MinE, GENESIS and the HSP cohort) or GRCh38 / hg38 (for Answer ALS, UCL and the 806 
LBC). GRCh37 is annotated to a non-canonical SARM1 cDNA and there are sequence 807 
irregularities compared to GRCh38 (see Figure 1 legend). Therefore, throughout this study 808 
we only report SARM1 genetic variation using numbering for genome build to GRCh38 and 809 
the canonical 724 amino acid SARM1 protein (having converted all GRCh37-based 810 
information from datasets that use that build). For this reason we also use population MAFs 811 
reported in gnomAD v3.1.1 in this study as it is referenced to GRCh38 (as opposed to 812 
gnomAD v2.1.1 which is referenced to GRCh37 and consequently contains a number of 813 
MAF discrepancies and additionally a lack of coverage for some alleles). 814 
 Many neurological disorders are represented in the complete GENESIS and UCL 815 
databases. Therefore, for the purposes of this study, our disease cohorts are restricted to 816 
individuals with motor nerve disorders and our control cohorts are restricted to unaffected 817 
individuals and individuals with non-neurological conditions. For GENESIS, the disease 818 
cohort consisted of individuals with ALS, pure or complex HSP, distal hereditary motor 819 
neuropathy and frontotemporal dementia with motor neuron disease, and the control cohort 820 
consisted of unaffected individuals, individuals with dilated cardiomyopathy and small 821 
numbers of individuals with metabolic or congenital disorders. For the UCL dataset, the 822 
disease cohort consisted of cases of spinal muscular atrophy and related disorders 823 
(including ALS), HSP and hereditary motor and sensory neuropathy, and the control cohort 824 
consisted of unaffected (control) individuals and a smaller number of individuals with Cluster 825 
headache syndrome. 826 
 Sample sequencing, variant calling and quality control methods for each dataset are 827 
broadly comparable. These are described elsewhere for Project MinE (Project MinE ALS 828 
Sequencing Consortium, 2018) and the LBC (Wragg et al., 2020). Information for SARM1 829 
variants in the Answer ALS project was obtained using ANNOVAR (Wang et al., 2010) 830 
annotation on GRCh38 positions, after read mapping with Burrows-Wheeler Alignment tool 831 
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(BWA) (Li & Durbin, 2010), variant calling with GATK (McKenna et al., 2010), and joint-832 
genotype using Sentieon (Freed et al., 2017). For GENESIS samples, Illumina WGS 833 
sequencing samples were aligned to the GRCh37 reference using BWA. Duplicate reads 834 
were marked using Picard’s MarkDuplicates utility. The bam file containing de-dupped reads 835 
was then used to call single nucleotide variations and indels using Freebayes, prior to 836 
October 2018, or later with GATK (v4). For the UCL rare disease dataset, exome 837 
sequencing was performed using the Agilent SureSelect Human All Exon V6 enrichment and 838 
enriched libraries underwent 150 base pair, paired-end sequencing on an Illumina HiSeqX10 839 
next-generation sequencing platform. Sequence data were aligned to GRCh38 and variant 840 
calling using GATK with filtering of PCR duplicates. For the HSP study samples. WES and 841 
WGS sequencing data were processed by GSvar pipeline (https://github.com/imgag/ngs-842 
bits) and sequencing files were aligned to GRCh37 human reference by BWA. Variants were 843 
called by GATK v4 with filtering of PCR duplicates. It was not feasible within the context of 844 
this study to validate variants by obtaining raw sequencing data or DNAs for Sanger 845 
sequencing but there is strong confidence in calling all variants tested in this study based on 846 
phred-scaled quality scores, when available. 847 
 Although complete ancestry information is not available to us, the vast majority of 848 
samples in all datasets used in this study, other than those in the GENESIS cohorts, are 849 
expected to be of predominantly European ancestry, and even within the GENESIS cohorts 850 
a smaller majority are expected to be of European origin. This is broadly supported by the 851 
observed frequency of the P332Q SARM1 allele in each cohort, an allele that is relatively 852 
more common in the European (non-Finnish) population than other populations (Table 3). As 853 
such, ancestry is not expected to have a substantial effect on the association statistics we 854 
have performed using aggregated data. 855 
 No new datasets or code were generated for this study. The Project MinE initiative data 856 
browser for Data Freeze 1 for searching genetic variation in patient and control cohorts was 857 
accessed at http://databrowser.projectmine.com/. Access to additional WGS / WES data in 858 
Project MinE (for DF2) and the other databases explored in this study was obtained upon 859 
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request. Researchers can apply for similar access via the following links or lead 860 
investigators (who can be contacted via the corresponding author): 861 
Project MinE - https://www.projectmine.com/research/data-sharing/ 862 
Answer ALS - https://www.nygenome.org/als-consortium/ 863 
GENESIS - https://neuropathycommons.org/genetics/genesis-platform 864 
UCL rare disease (neurology) dataset - Prof. Henry Houlden (listed author). 865 
HSP study - Dr. Rebecca Schüle (listed author).  866 
Lothian Birth Cohort - https://www.ed.ac.uk/lothian-birth-cohorts/data-access-collaboration  867 
There may be restrictions for commercial companies in some cases. 868 
 869 
Patient details 870 
This is a retrospective study using anonymised data so specific consent was not obtained by 871 
the authors, but consent was obtained at each site that contributed patient information to this 872 
study in accordance with their local Institutional Review Boards (IRBs). Patient information 873 
for the Answer ALS project patients (patient IDs NEUMA411HJP and NEUBD218YR3) was 874 
already publicly available at https://dataportal.answerals.org/search. 875 
 876 
Statistics 877 
Multiple comparisons, multiple paired t tests and one- or two-way ANOVA were performed 878 
using Prism software (GraphPad Software Inc., La Jolla, CA, USA) as described in the figure 879 
legends. Log transformation of the data was performed prior to statistical testing where 880 
appropriate as indicated in figure legends and source data files; however, non-transformed 881 
data were plotted on graphs in all Figures for ease of interpretation. A p-value of <0.05 was 882 
considered significant and values above this cut-off are considered not significant (ns). For 883 
tests applying a false discovery rate (FDR) correction, the adjusted p-value we report is the 884 
q-value.  885 
 To determine whether there is a burden of rare variants (minor allele frequency <0.01) in 886 
the SARM1 gene based on their functional properties (as determined in this study), we 887 
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performed burden and optimized sequence kernel association test (SKAT-O) as 888 
implemented in the SKAT-O R package (S. Lee et al., 2012). ‘Burden’ refers to a linear sum 889 
of χ2 random variables where each variable is assigned a genetic variant (Davies, 1980). 890 
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FIGURE LEGENDS 1226 
 1227 
Figure 1. SARM1 coding variants in ALS patient and control groups. 1228 
Schematic representation of the canonical 724 amino acid human SARM1 protein showing 1229 
basic domain structure and the approximate locations of the coding variation present in the 1230 
Project MinE DF1 and Answer ALS datasets. Variants are separated into those seen only in 1231 
ALS patients, those seen in ALS patients and controls (both), and those seen only in 1232 
controls. MTS, "mitochondrial" targeting sequence; ARM, HEAT/Armadillo motif domain; 1233 
SAM, sterile alpha motif domains; TIR, Toll/Interleukin receptor domain. 1234 
Special note: Variants are annotated according to the canonical 724 amino acid SARM1. 1235 
Project MinE DF1 currently uses gnomAD v2.1.1, which is based on genome build GRCh37 1236 
/ hg19, and annotates variants to a 690 amino acid product of a non-canonical reference 1237 
SARM1 cDNA sequence. This cDNA, and genome build GRCh37, contain single nucleotide 1238 
substitutions, insertions and deletions at its 5' end when compared to gnomAD v3.1.1 and 1239 
GRCh38 / hg38 which annotate to the canonical 724 amino acid SARM1. These differences 1240 
mean that the 690 amino acid "isoform" has a truncated N-terminus, due to use of an 1241 
alternative ATG codon, and switches frame until it eventually synchronises with 724 amino 1242 
acid SARM1 at amino acid 107 (73 in the 690 amino acid "isoform"). As such, numbering of 1243 
SARM1 variants in Project MinE DF1 (and any databases annotated to gnomAD v2.11 / 1244 
GRCh37) is 34 residues lower than that shown here over the synchronised region and 1245 
differences more N-terminal to this must be determined individually by lift over from GRCh37 1246 
to GRCh38. Notably, the NCBI Single Nucleotide Polymorphism Database (dbSNP, 1247 
including rsIDs) uses numbering based on the 724 amino acid SARM1 protein.  1248 
 1249 
Figure 2. Several ALS patient-specific SARM1 ARM domain coding variants in Project 1250 
MinE increase NAD+ depletion in transfected HEK 293T cells. 1251 
(A-C) Levels of NAD+ (A), NADP+ (B) and ATP (C) in extracts of HEK 293T cells 24 h after 1252 
transfection with expression constructs for Flag-tagged WT or variant SARM1 (as listed). 50 1253 
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ng SARM1 vector combined with 750 ng empty vector (24-well plate format) was transfected 1254 
for optimal assay conditions (see Figure 2 - Figure supplement 1). Data are shown as a 1255 
proportion of levels in cells transfected with empty vector (ev) alone performed in parallel 1256 
(set at 1, grey dashed line). Means ±SEM with individual data points are plotted (n=4 or 5). 1257 
*p<0.05, **p<0.01 and ***p<0.001, multiple pairwise comparisons to WT SARM1 with FDR 1258 
correction (after log transformation of data in parts A and B). Bars for WT SARM1, and the 1259 
P332Q and N337D SARM1 variants, which are seen in both patient and control groups in 1260 
Project MinE, are hatched to differentiate them from patient-specific variants (bold text, filled 1261 
bars). 1262 
(D) Representative immunoblots of the extracts described in parts A-C showing Flag-tagged 1263 
WT or variant SARM1, ZsGreen (co-expressed with the exogenous SARM1 from a 1264 
bicistronic mRNA) and GAPDH (acting as a loading control). Molecular weight markers 1265 
(kDa) are shown on the right of each panel. Four times the amount of extract and enhanced 1266 
detection was needed to detect SARM1 variants that cause the greatest NAD+ depletion 1267 
(bottom right blot). 1268 
(E) Representative ZsGeen fluorescence and phase contrast imaging of HEK 293T cells 24 1269 
h after transfection with WT or Δ229-235 SARM1 expression constructs (brightness and 1270 
contrast have been increased equally in each pair of images to enhance visualisation). 1271 
Reduced ZsGreen signal intensity, as seen here for Δ229-235 SARM1, was consistently 1272 
seen (n=5) for variants that reduced NAD+ levels more than WT SARM1. 1273 
Figure supplements: Figure 2 - figure supplement 1. Optimisation of transfection 1274 
conditions for assessing SARM1-dependent NAD+ consumption in HEK 293T cells; Figure 2 1275 
- figure supplement 2. Truncated forms of putative strong GoF SARM1 variants are not 1276 
detected in transfected HEK 293T cells and supressed expression of the full-length proteins 1277 
and co-expressed zsGreen is increased by boosting NAD+ production with NR; Figure 2 - 1278 
figure supplement 3. Cell density-dependent death of transfected HEK 293T cells 1279 
expressing SAM-TIR fragment. 1280 
 47 
Source data: Figure 2 - source data 1. Source data in excel for Figure 2A, 2B and 2C; 1281 
Figure 2 - source data 2. Source data in excel for Figure 2 - figure supplement 2B. 1282 
 1283 
Figure 3. Constitutive NADase activity and NMN responsiveness of SARM1 ARM 1284 
domain variants in Project MinE. 1285 
Each panel is designed to show different statistical comparisons and some of the same data 1286 
are used in different tests, as described. WT SARM1, and P332Q and N337D SARM1 (seen 1287 
in both patient and control groups in Project MinE), are shown as hatched bars throughout to 1288 
differentiate them from patient-specific variants (bold text, filled bars).  1289 
(A) and (B) Constitutive (basal) NADase activities of immunoprecipitated WT SARM1, 1290 
variant SARM1, or SAM-TIR fragment (as indicated) in the presence of 25 µM NAD+. In part 1291 
A, data for variants with high or low NADase activity, obtained in parallel, are plotted 1292 
separately, against different scales, to more clearly show all differences relative to WT 1293 
SARM1 (included on both). Means ±SEM with individual data points (n=4 or 5) are plotted. 1294 
*p<0.05, **p<0.01, ***p<0.001 and ns (not significant) = p>0.05, multiple pairwise 1295 
comparisons to WT SARM1 with FDR correction for part A and one-way ANOVA with 1296 
Tukey's correction for part B (both after log transformation). 1297 
(C) Activation of SARM1 NADase by 50 µm NMN (in the presence of 25 µM NAD+). 1298 
Constitutive activities (no NMN) are as in part A with rates +NMN calculated from assays 1299 
performed in parallel. High and low NADase activity variants are plotted separately (as in 1300 
part A). Means ±SEM with individual data points (n=4 or 5) are plotted. *p<0.05 and 1301 
**p<0.01, multiple paired t tests of rates ±NMN with FDR correction (after log 1302 
transformation). 1303 
(D) Activation of SARM1 NADase by 10 or 50 µm NMN (in the presence of 25 µM NAD+). 1304 
NMN-insensitive variants with very high constitutive NADase activity were not tested. 1305 
Constitutive and +50 µM NMN activities are a subset of those shown in part B and are only 1306 
those from assays performed in parallel with 10 µM NMN. Means ±SEM with individual data 1307 
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points (n=4) are plotted. *p<0.05, **p<0.01 and ***p<0.001, two-way ANOVA with Šidák's 1308 
correction (after log transformation). 1309 
Figure supplements: Figure 3 - figure supplement 1. Purification of recombinant SARM1 1310 
proteins for use in NADase assays; Figure 3 - figure supplement 2. Relative NMN 1311 
responsiveness of Project MinE DF1 SARM1 ARM domain variants. 1312 
Source data: Figure 3 - source data 1. Source data in excel for Figure 3A, 3B, 3C and 3D; 1313 
Figure 3 - source data 2. Source data in excel for Figure 3 - figure supplement 2A, 2B, 2C 1314 
and 2D. 1315 
 1316 
Figure 4. Functional characterisation of additional ARM domain and other N-terminal 1317 
SARM1 coding variants in the Answer ALS database and Project MinE DF1. 1318 
Bars for WT and variants that are only seen in controls are hatched throughout to 1319 
differentiate them from patient-specific variants (bold text, filled bars). 1320 
(A) NAD+ levels in extracts of HEK 293T cells 24 h after transfection with expression 1321 
constructs for Flag-tagged WT or variant SARM1 (as listed). Details are as per Figure 2. 1322 
Means ±SEM with individual data points (n=7) are plotted. *p<0.05, **p<0.01 and 1323 
***p<0.001, multiple pairwise comparisons to WT SARM1 with FDR correction (after log 1324 
transformation). 1325 
(B) Representative immunoblots of extracts as described in part A. Blots were probed as in 1326 
Figure 2D. Four times the amount of extract and enhanced detection was needed to detect 1327 
R267W SARM1 (right). Molecular weight markers (kDa) are shown on the right of each 1328 
panel. 1329 
(C) and (D) Constitutive NADase activities (at 25 µM NAD+) of recombinant WT and variant 1330 
SARM1, as indicated. Predicted strong GoF R267W SARM1 was compared directly to WT 1331 
SARM1 and strong NADase GoF Δ229-235 SARM1 in part C, separately from the other 1332 
variants in part D. Means ±SEM with individual data points (n=4 or 5) are plotted. *p<0.05, 1333 
**p<0.01, ***p<0.001 and ns (not significant) = p>0.05, one-way ANOVA with Tukey's 1334 
 49 
correction (after log transformation) in part C and multiple pairwise comparisons to WT 1335 
SARM1 with FDR correction in part D. 1336 
(E) and (F) Activation of the NADase activity of recombinant WT and variant SARM1, as 1337 
indicated, by 50 µm NMN (in the presence of 25 µM NAD+). Constitutive activities (no NMN) 1338 
are as in parts C and D with rates +NMN calculated from assays performed in parallel. 1339 
Means ±SEM with individual data points (n=4 or 5) are plotted. *p<0.05 and **p<0.01, 1340 
multiple paired t tests of rates ±NMN with FDR correction (after log transformation in part E). 1341 
Source data: Figure 4 - source data 1. Source data in excel for Figure 4A, 4C, 4D, 4E and 1342 
4F. 1343 
 1344 
Figure 5. Δ229-235 SARM1 retains its strong NADase GoF properties in complexes 1345 
with WT SARM1. 1346 
(A) NAD+ levels in extracts of HEK 293T cells 24 h after transfection with individual 1347 
expression constructs or mixtures of constructs for HA- or Flag-tagged WT SARM1 and/or 1348 
Flag-tagged Δ229-235 SARM1. Details as per Figure 2, except that 50 ng SARM1 vector 1349 
was combined with 750 ng empty vector for single constructs and 25 ng each for mixtures. 1350 
Means ±SEM with individual data points (n=5) are plotted. **p<0.01, ***p<0.001 and ns (not 1351 
significant) = p>0.05, one-way ANOVA with Tukey's correction (after log transformation). 1352 
Only relevant comparisons are shown. 1353 
(B) Representative immunoblots of extracts as described in part A. Duplicate blots were 1354 
probed with Flag or HA antibodies to independently assess levels of co-expressed Flag- or 1355 
HA-tagged WT or Flag-tagged Δ229-235 SARM1. Both blots were probed for ZsGreen and 1356 
GAPDH (acting as a loading control) to confirm the blots were representative replicates. A 1357 
faint, non-specific cross-reaction of the HA antibody to Flag-tagged SARM1 was consistently 1358 
seen under the conditions used (WT-Flag only lane). Molecular weight markers (kDa) are 1359 
shown on the right of each panel. 1360 
(C) Representative immunoblots (of n=3) of reciprocal co-immunoprecipitation of HA-tagged 1361 
WT SARM1 with Flag-tagged WT or Δ229-235 SARM1. Immunoprecipitations using Flag or 1362 
 50 
HA antibodies or no antibody were performed on the same extracts of transfected HEK 293T 1363 
cells co-expressing HA-tagged WT SARM1 with Flag-tagged WT or Flag-tagged Δ229-235 1364 
SARM1 (from equal amounts of construct), or expressing individual proteins. Duplicate 1365 
immunoblots of immunoprecipitated proteins, and the original extracts used in the 1366 
immunoprecipitations (input), were probed with Flag or HA antibodies. A small amount of 1367 
non-specific binding of tagged proteins to protein A/G beads was consistently seen for inputs 1368 
with the highest expression levels. Molecular weight markers (kDa) are shown on the right of 1369 
each panel. 1370 
(D) Constitutive NADase activity (in the presence of 25 µM NAD+) of immunoprecipitated WT 1371 
+ Δ229-235 SARM1 complexes compared to WT or Δ229-235 SARM1 alone. All proteins 1372 
were Flag-tagged to ensure complete immunoprecipitation of complexes of WT and Δ229-1373 
235 SARM1. Means ±SEM with individual data points (n=4) are plotted. *p<0.05 and 1374 
**p<0.01, one-way ANOVA with Tukey's correction (after log transformation). 1375 
(E) Inducibility of immunoprecipitated WT + Δ229-235 SARM1 complexes and WT or Δ229-1376 
235 SARM1 alone by 50 µm NMN (in the presence of 25 µM NAD+). Constitutive activities 1377 
(no NMN) are as in part D with rates +NMN calculated from assays performed in parallel. 1378 
Means ±SEM with individual data points (n=4) are plotted. **p<0.01, multiple paired t tests of 1379 
rates ±NMN with FDR correction (after log transformation). 1380 
Source data: Figure 5 - source data 1. Source data in excel for Figure 5A, 5D and 5E. 1381 
 1382 
Figure 6. Strong NADase GoF Δ229-235 SARM1 reduces SCG neuron viability under 1383 
mild stress conditions. 1384 
(A) Representative images of DsRed-positive wild-type SCG neurons 24 h after 1385 
microinjection with expression constructs for WT or Δ229-235 SARM1 and DsRed (at 2.5 1386 
ng/µl and 40 ng/µl in the injection mix, respectively), with or without supplementation of the 1387 
culture medium with 2 mM NR at the time of injection. Equal numbers of neurons were 1388 
injected. 1389 
 51 
(B) Quantification of DsRed-positive neurons for the conditions described in part A. Means 1390 
±SEM with individual data points (n=5 or 17) are plotted. *p<0.05 and ***p<0.001, one-way 1391 
ANOVA with Tukey's correction. Only relevant comparisons are shown. 1392 
(C) Time course of survival of DsRed-positive neurons after manipulation of culture 1393 
conditions as indicated. Neurons were injected as in part A and maintained in medium 1394 
containing NR. Manipulations were performed 24 h after injection which corresponds to time 1395 
0 on the graphs. Survival of injected, DsRed-labelled neurons was assessed as described in 1396 
part D and is expressed as a percentage of those present at time 0. Means ±SEM (n=4 or 5) 1397 
are plotted. ***p<0.001, two-way ANOVA with Šidák's correction. 1398 
(D) Representative images for data presented in part C. Only one representative condition is 1399 
shown for neurons injected with the WT SARM1 construct. Survival of DsRed-positive 1400 
neurons was assessed by comparing signal intensity and neuron size / shape at different 1401 
timepoints, a method that provides an accurate reflection of survival rates (Gilley & 1402 
Coleman, 2010). 1403 
Figure supplements: Figure 6 - figure supplement 1. Microinjection of 2.5 ng/µl WT 1404 
SARM1 expression construct provides expression that is functionally relevant; Figure 6 - 1405 
figure supplement 2. Injection of empty vector does not affect SCG neuron viability. 1406 
Source data: Figure 6 - source data 1. Source data in excel for Figure 6B and 6C; Figure 6 1407 
- source data 2. Source data in excel for Figure 6 - figure supplement 1A, and Figure 6 - 1408 
figure supplement 2A and 2B. 1409 
 1410 
Figure 7. NADase activity is required for the pro-death effects of Δ229-235 SARM1 in 1411 
SCG neurons. 1412 
(A) Relative levels of NAD+ in extracts of HEK 293T cells 24 h after transfection with 1413 
expression constructs for WT, E642A, Δ229-235 or Δ229-235/E642A SARM1, as per Figure 1414 
2. Means ±SEM with individual data points (n=4) are plotted. *p<0.05, **p<0.01, ***p<0.001 1415 
and ns = p>0.05, one-way ANOVA with Tukey's correction (after log transformation). Only 1416 
relevant comparisons are shown. 1417 
 52 
(B) Representative immunoblots of extracts as described in part A. Blots were probed as in 1418 
Figure 2D. Molecular weight markers (kDa) are shown on the right of each panel. 1419 
(C) Numbers of DsRed-positive neurons 24 h after microinjection with expression constructs 1420 
for Δ229-235 SARM1 or Δ229-235/E642A SARM1 and DsRed (at 2.5 ng/µl and 40 ng/µl in 1421 
the injection mix, respectively), with or without supplementation of the culture medium with 2 1422 
mM NR at the time of injection. Equal numbers of neurons were injected. Means ±SEM with 1423 
individual data points (n=4) are plotted. **p<0.01, ***p<0.001 and ns (not significant) = 1424 
p>0.05, one-way ANOVA with Tukey's correction. Only relevant comparisons are shown. 1425 
(D) Time course of survival of DsRed-positive neurons injected as in part C and maintained 1426 
in medium containing NR prior to removal of NR and addition of 100 nM FK866 24 h after 1427 
injection (corresponding to time 0 on the graphs). Survival of injected neurons was assessed 1428 
as described in Figure 5D and is expressed as a percentage of those present at time 0. 1429 
Means ±SEM (n=4) are plotted. ***p<0.001, two-way ANOVA with Šidák's correction. 1430 
Source data: Figure 7 - source data 1. Source data in excel for Figure 7A, 7C and 7D. 1431 





























            
  T39M  rs988047470  28372148 C>T  0     1 
ARM 
 L76fs  -  28372255 del  0     1 
 V88M  rs1555584160  28372294 G>A  0     1 
 V112I  rs1032963037  28372366 G>A  0.000015    1  
 L223P  -  28381400 T>C  0    1  
 229-235 d  rs782325355  28381417_37 del  0.000059    2  
 A240E  rs1449836804  28381451 C>A  0.000015    1  
 R244S  -  28381462 C>A  0    1  
 249-252  -  28381475_86 del  0    1  
 A250T  rs1555585243  28381480 G>A  0    1  
 A275V  rs376587698  28381556 C>T  0.000029    1  
 A301S  rs782606059  28381633 G>T  0.00012    3  
 R310H  rs369186722  28381661 G>A  0.00016    1  
 V331E  rs1555585331  28381724 T>A  0    1  
 P332Q  rs140811640  28381727 C>A  0.012    107   47 
 N337D  rs375690432  28381741 A>G  0.00038    3   1 
 E340K  rs781854217  28381750 G>A  0.000059    1  
 A341V  rs373458416  28381754 C>T  0.00012    2  
 T385A  rs2068039068  28384420 A>G  0    1  
SAM 
 Q418H  rs1194545365  28384521 G>T  0.000029    1   1 
 Y429F  -  28384553 A>T  0     1 
 E431G  rs1555585662  28384559 A>G  0    1  
 R465T  -  28385039 G>C  0    1  
 C482Y  -  28385090 G>A  0     1 
 R484C  rs1555585809  28385095 C>T  0    1  
 A488E  rs782228906  28385108 C>A  0.00012    2  
 Y501H  rs144613221  28385146 T>C  0.0029    32   13 
 T502P  rs782421919  28385149 A>C  0.000074    1  
 V518L  rs782106973  28385197 G>C  0.000088    3  
  S558N  -  28388216 G>A  0     1 
TIR 
 R569C  rs571724138  28388248 C>T  0.000029    1  
 R615H  rs782753946  28388460 G>A  0.000044     1 
 G624*  rs141324431  28388486 G>T  0.000073     1 
 D637Y  rs1451417529  28388525 G>T  0    1  
 A646S  rs782676389  28395917 G>T  0    1  
 Q673*  -  28395998 C>T  0    1  
  A719V  rs146812537  28396267 C>T  0.00050     2 
  G722V  rs1298702390  28396276 G>T  0    1   1 
 1433 
 1434 
Table 1. SARM1 coding variants in Project MinE DF1. 1435 
a
 numbering based on the canonical 724 amino acid human SARM1. 1436 
b
 numbering according to GRCh38 after lift over from GRCh37 which contains sequence 1437 
discrepancies that result in anomalous numbering (see Figure 1 legend and Materials and Methods). 1438 
c
 minor allele frequency for European (non-Finnish) population in gnomAD v3.1.1 as the best ethnicity 1439 
match for this dataset. 1440 
d
 This variant is reported as Δ226-232 elsewhere (Bloom et al., 2021). At the DNA level the deletion 1441 
encompasses a 32-bp region with 11-bp identical repeats at each end and, as such, any 21-bp 1442 
deletion within this region will have an identical effect at both the DNA and protein level. Δ226-232 1443 
and Δ229-235 are thus identical proteins. We have used the Δ229-235 nomenclature for consistency 1444 
with its rsID. 1445 
All ARM domain and other N-terminal variants, barring L76fs, have been tested for function in this 1446 
study. 1447 
An additional frameshift variant (corresponding to 28372175dup, G46fs, rs11437592) was reported, 1448 
but it appears to be an artefact due to sequence discrepancies in the GRCh37 genome build. 1449 





























            
  G35E  rs1480321233  28372136 G>A  0.000015    1  
ARM 
 R131G  rs1389320808  28372423 C>G  0.000015    1  
 A210V  -  28381361 C>T  0     1 
 229-235 †  rs782325355  28381417_37 del  0.000059    1  
 R267W  rs11658194  28381531 C>T  0.000015    1  
 A301S 
†
  rs782606059  28381633 G>T  0.00012    1  
 P332Q 
†
  rs140811640  28381727 C>A  0.012    16   3 
SAM  Y501H
 †
  rs144613221  28385146 T>C  0.0029    5   5 
TIR  S684F  rs782256561  28396162 C>T  0.000044    1  
  A719V
 †
  rs146812537  28396267 C>T  0.00050    1  
 1451 
 1452 
Table 2. SARM1 coding variants in Answer ALS. 1453 
a
 numbering based on the canonical 724 amino acid human SARM1. 1454 
b
 numbering according to genome build GRCh38. 1455 
c
 minor allele frequency for European (non-Finnish) population in gnomAD v3.1.1 as the best ethnicity 1456 
match for this dataset. 1457 
†
 Variants also present in the Project Mine DF1 dataset. 1458 
All ARM domain and other N-terminal variants have been tested for function in this study. 1459 





















































































































































































  MinE DF1 8,732  1 2 1 - 1 1 1 7  - - - - 1 - - 1 1 1 1 3 1 3 2 14  107 
  Answer ALS 1,412  - 1 - 1 - - - 2  1 - - - - 1 - - - - - 1 - - - 3  16 
  MinE DF2+
 a 
3,176  - - - - - - 1 1  - - - - - - - - - - - - 1 - - 1  40 
  GENESIS 5,936  - 2 - - - - - 2  - - - - - - - - - - - - - - 1 1  15 
  UCL 1,366  - - - 1 - - - 1  - - - - - - - - - - - 2 - - - 2  5 
  HSP study 1,612  - - - - - - - 0  - - - - - - - - - - - - - - - 0  15 
  Total 22,234 1 5 1 2 1 1 2 13  1 0 0 0 1 1 0 1 1 1 1 6 2 3 3 21  198 








  MinE DF1 3,664 - - - - - - - 0  - 1 1 1 - - - - - - - - - 1 - 4  47 
  Answer ALS 184 - - - - - - - 0  - - - - - - 1 - - - - - - - - 1  3 
  MinE DF2+
 a 
812 - - - - - - - 0  - - - - - - - - - - - - - - 1 1  15 
  GENESIS 7,330 - - - - - - - 0  - - - - - - - - - - 1 - - 1 1 3  58 
  UCL 3,616 - - - - - - - 0  - - - - - - - - - - 1 1 2 - - 4  38 
  HSP study 2,490 - - - - - - - 0  - - - - - - - - - - - - - - - 0  19 
  LBC
 
2,708 - - - - - - - 0  - - - - - - - - - - - - - 2 - 2  26 
  Total 20,804 0 0 0 0 0 0 0 0  0 1 1 1 0 0 1 0 0 0 2 1 2 4 2 15  206 
 1461 
 1462 
Table 3. Occurrences of SARM1 alleles encoding ARM domain and other N-terminal variants in 1463 
individual datasets. 1464 
a 
Extra samples in Project MinE DF2 that were not part of DF1. 1465 
b 
MAFs for the P332Q SARM1 allele in each dataset (in cases plus controls combined) of 0.012 (MinE 1466 
DF1), 0.012 (Answer ALS), 0.014 (MinE DF2 extras), 0.0055 (GENESIS), 0.0086 (UCL), 0.0010 1467 
(LBC) and 0.0083 (HSP study) are, barring the more ethnically-diverse GENESIS cohorts, broadly 1468 
consistent with each dataset containing predominantly European samples as the European MAF of 1469 
0.012 is substantially higher than in other populations (gnomAD v3.1.1). 1470 
  1471 
 56 
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Controls  Cases Controls 
   /22,234 /20,804 /63,882     
  Strong L223P  1 0 0  0.000045 0 0 
  GoF 229-235  5 0 4  0.00022 0 0.000063 
 249-252  1 0 0  0.000045 0 0 
 R267W  2 0 1  0.000090 0 0.000016 
 V331E  1 0 0  0.000045 0 0 
 E340K  1 0 4  0.000045 0 0.000063 
 T385A  2 0 0  0.000090 0 0 
          
 Combined  13 0 9  0.00058 0 0.00014 
          
  Other G35E  1 0 1  0.000045 0 0.000016 
 T39M  0 1 0  0 0.000048 0
 
 L76fs  0 1 0  0 0.000048 0 
 V88M  0 1 0  0 0.000048 0
 
 V112I  1 0 1  0.000045 0 0.000016 
 R131G  1 0 1  0.000045 0 0.000016 
 A210V  0 1 0  0 0.000048 0 
 A240E  1 0 0  0.000045 0 0 
 R244S  1 0 0  0.000045 0 0 
 A250T  1 0 0  0.000045 0 0
 
 A275V  1 2 2  0.000045 0.000096 0.000031 
 A301S  6 1 8  0.00027 0.000048 0.00013 
 R310H  2 2 11  0.000090 0.000096 0.00017 
 N337D  3 4 26  0.00013 0.00019 0.00041 
 A341V  3 2 8  0.00013 0.000096 0.00013 
          
 Combined  21 15 58  0.00094 0.00072 0.00091 
          
* P332Q  198 206 789  0.0089 0.010 0.012 
 1472 
 1473 
Table 4. Occurrences and MAFs of SARM1 alleles encoding ARM domain and other N-terminal 1474 
variants aggregated from all datasets used in this study. 1475 
a
 Aggregated values for all datasets listed in Figure 3 - Figure supplement 1. 1476 
b
 Values for the non-neuro European (non-Finnish) population in gnomAD v3.1.1. These values do 1477 
not include case samples collected as part of a neurologic or psychiatric case/control study. However, 1478 
that does not guarantee that any carriers of the alleles listed are not already affected or will not go on 1479 
to develop a motor nerve disorder. 1480 
















Other observations /  
co-morbidities 
ALS (bulbar) L223P Project MinE M 59 / 3 yr. dead None a Not known  
ALS (bulbar) 229-235 Answer ALS F 70 / 2 yr. dead None b Not known - No FTD 
- Hyperlipidaemia 
ALS 229-235 GENESIS M 66 / 1 yr. dead *SOD1 None - Rapid progression 




- lower extremity onset 
- FTD 
ALS (spinal) 229-235 Project MinE M 42 / 3 yr. dead None a Not known  
ALS (spinal) 229-235 Project MinE M 57 / 3 yr. dead None a Not known  
ALS (bulbar) 249-252 Project MinE M 65 / 4 yr. dead None a Not known  
ALS (spinal) R267W Answer ALS M 58 / 2 yr. dead **FIG4 b Not known 
- lower limb onset 
- COPD and Type II diabetes 
ALS (spinal) V331E Project MinE M 53 / 5 yr. dead None a Not known  
ALS (spinal) E340K Project MinE M 75 / 6 yr. dead None a Not known  
ALS (spinal) T385A Project MinE M 69 / 6 yr. alive None a Not known  
ALS (bulbar) T385A Project MinE F 63 / 1 yr. dead None a Not known  
HSP (pure) 229-235 GENESIS F 5 / 14 yr. alive Not 
available 
None 
- Presented with lower extremity 
spasticity and hyperreflexia 
extensor plantar responses 
- Wheelchair use at 19 yr. 
- Normal total spine MRI      





R267W UCL M 40 / 25 yr. alive None c None 
- Presented with right leg 
weakness, thigh fasciculations 
and slowly progressive wasting 
- No sensory, bladder, bowel, or 
bulbar involvement 
- Mild hand weakness and brisk 
reflexes by 50 yr. 
- Lower limb spasticity by 61 yr. 
- Still ambulates independently 
- Proximal lower limb denervation 
> distal upper limb denervation. 
ALS (spinal) V112I Project MinE M 52 / 17 yr. dead None a  Not known  
 1482 
 1483 
Table 5. Clinical information for motor nerve disorder patients heterozygous for SARM1 GoF 1484 
alleles. 1485 
* Heterozygous for the partially-penetrant I114T SOD1 variant associated with sporadic ALS 1486 
** Heterozygous for the L17P FIG4 variant, a variant that has previously only been associated with 1487 
CMT4J in combination with a null allele. 1488 
a 
Screened for variation in C9orf72, FUS, SOD1 and TARDBP. 1489 
b 
Screened for variation in ALS2, ATXN2, C9orf72, CCNF, CHCHD10, FUS, OPTN, PFN1, SOD1, 1490 
TARDBP, TBK1, UBQLN2, VAPB and VCP. 1491 
c 
Screened for variation in Androgen Receptor expansion, ALS2, ANG, C9orf72, CYP7B1, DCTN1, 1492 
FA2H, FIG4, FUS, GJC2, KIAA0196, KIF5A, NIPA1, OPTN, PLP1, PNPLA6, REEP1, RTN2, SPAST, 1493 
SPG7, SLC52A1, SLC52A2, SLC52A3, SMN, SOD1, TARDBP, UBQLN2, VAPB, VCP, whole mtDNA 1494 
sequencing in blood. 1495 
FTD; frontotemporal dementia, COPD; chronic obstructive pulmonary disease 1496 
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